A consortium led by the University of Southampton has received funding to develop next-generation treatments for cancer and chronic inflammation.

A major UK study, led by researchers at the University of Oxford’s Nuffield Department of Primary Care Health Sciences, Oxford University Hospitals NHS Foundation Trust, the National Institute for Health and Care Research (NIHR) Oxford Biomedical Research Centre, and Oxford Cancer, has provided the most comprehensive analysis to date of a cancer diagnosis pathway for patients presenting with non-specific symptoms (NSS), such as unexplained weight loss or fatigue. These symptoms can indicate a wide range of conditions, from benign diseases to late-stage cancers, making timely and accurate diagnosis a significant challenge in primary care.

To improve treatment rates for these patients, UCSF researchers designed a CAR T cell therapy and combined it with an older class of diabetes drugs called thiazolidinediones, to enhance NECTIN4 expression and make tumor cells more susceptible to NECTIN4-CAR T therapy.  

CLEVELAND, Ohio (September 10, 2025)—Despite evidence suggesting the safety of hormone therapy for patients with a history of low-grade endometrial or epithelial ovarian cancer, a new survey shows that many gynecologists and some gynecologic oncologists are still uncomfortable prescribing the therapy for this patient population. This indicates a need for more clinician education to help overcome lingering misconceptions. Results of the survey are published online today in Menopause, the journal of The Menopause Society.

New research from the Exercise Medicine Research Institute at Edith Cowan University (ECU) has highlighted that children undergoing cancer treatment often lose skeletal muscle at a time when they should be rapidly gaining it, a loss that could increase treatment complications and raise the risk of long-term health problems. 

Mass General Brigham researchers have developed a new liquid biopsy tool, HPV-DeepSeek, that can detect HPV-associated head and neck cancers up to 10 years before symptoms appear, potentially enabling earlier and less aggressive treatment. The test uses whole-genome sequencing to identify microscopic fragments of HPV DNA in the bloodstream and has demonstrated high accuracy and specificity in early detection.